NCT03162900 - A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

September 23, 2017

Study Completion Date

October 16, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

Glasdegib Therapeutic Exposure

Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.

DRUG

Glasdegib Supra-therapeutic Exposure

Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.

DRUG

Positive Control (Moxifloxacin)

Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.

OTHER

Placebo Control

Subjects will receive placebo dose followed by ECG and PK assessments.

Trial Locations (1)

Pfizer Clinical Research Unit, Brussels